Guizhou Xinbang Pharmaceutical Co., Ltd. (SHE:002390)
China · Delayed Price · Currency is CNY 3.300
+0.120 (3.77%)
Apr 29, 2026, 3:04 PM CST
SHE:002390 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 191.8 | 101.38 | 287.23 | 224.37 | 272.87 |
Depreciation & Amortization | 202.22 | 214.07 | 236.71 | 243.55 | 247.33 |
Other Amortization | 14.32 | 20.92 | 19.12 | 26 | 28.26 |
Loss (Gain) From Sale of Assets | 3.48 | 2.29 | -0.02 | 0 | 0.42 |
Asset Writedown & Restructuring Costs | 24.2 | 1.11 | 0.56 | 2.13 | 4.04 |
Loss (Gain) From Sale of Investments | -19.74 | -2.93 | -9.4 | -37.43 | -3.92 |
Provision & Write-off of Bad Debts | - | 49.57 | 64.92 | 40.61 | 26.68 |
Other Operating Activities | 113.22 | 102.8 | 108.47 | 127.69 | 204.77 |
Change in Accounts Receivable | 288.64 | 334.13 | 103.29 | 94.98 | -609.77 |
Change in Inventory | 147.63 | -63.64 | 24.42 | -97.01 | -92.31 |
Change in Accounts Payable | -204.41 | -116.89 | -33.65 | -108.32 | 372.58 |
Change in Other Net Operating Assets | - | - | - | 80.84 | 16.13 |
Operating Cash Flow | 732.53 | 634.97 | 790.62 | 590.8 | 457.97 |
Operating Cash Flow Growth | 15.37% | -19.69% | 33.82% | 29.00% | -38.29% |
Capital Expenditures | -85.42 | -124.87 | -135.78 | -158.78 | -253.76 |
Sale of Property, Plant & Equipment | 6.33 | 2.65 | 134.98 | 0.55 | 0.87 |
Cash Acquisitions | - | - | - | - | -296.17 |
Divestitures | - | - | 36.55 | 1.61 | 0.68 |
Investment in Securities | 20.74 | 3.1 | 3.07 | 4.63 | -242.55 |
Other Investing Activities | 19.83 | 4.08 | 11.44 | 33.97 | 46.59 |
Investing Cash Flow | -38.51 | -115.03 | 50.26 | -118.02 | -744.34 |
Short-Term Debt Issued | - | 895.1 | 1,211 | 1,985 | 2,112 |
Long-Term Debt Issued | 440 | - | - | - | - |
Total Debt Issued | 440 | 895.1 | 1,211 | 1,985 | 2,112 |
Short-Term Debt Repaid | - | -900.1 | -1,817 | -2,019 | -4,257 |
Long-Term Debt Repaid | -766.2 | - | - | - | - |
Total Debt Repaid | -766.2 | -900.1 | -1,817 | -2,019 | -4,257 |
Net Debt Issued (Repaid) | -326.2 | -5 | -606.19 | -34.1 | -2,145 |
Issuance of Common Stock | - | - | - | - | 1,505 |
Repurchase of Common Stock | - | -78.99 | -141.4 | - | - |
Common Dividends Paid | -130.82 | -192.29 | -158.23 | -168.36 | -230.34 |
Other Financing Activities | -130.19 | -41.63 | -1.38 | 13.03 | -39.76 |
Financing Cash Flow | -587.21 | -317.91 | -907.2 | -189.42 | -910.57 |
Foreign Exchange Rate Adjustments | 0 | -0 | 0 | 0 | -0 |
Net Cash Flow | 106.81 | 202.03 | -66.32 | 283.35 | -1,197 |
Free Cash Flow | 647.11 | 510.1 | 654.84 | 432.02 | 204.21 |
Free Cash Flow Growth | 26.86% | -22.10% | 51.58% | 111.56% | -66.19% |
Free Cash Flow Margin | 11.52% | 8.46% | 10.13% | 6.80% | 3.16% |
Free Cash Flow Per Share | 0.34 | 0.25 | 0.34 | 0.23 | 0.11 |
Cash Income Tax Paid | 243.52 | 222.01 | 236.11 | 227.09 | 258.49 |
Levered Free Cash Flow | 740.78 | 597.17 | 569.17 | 314.65 | -37.54 |
Unlevered Free Cash Flow | 740.78 | 611.88 | 593.98 | 347.02 | 25.08 |
Change in Working Capital | 203.04 | 145.76 | 83.02 | -36.13 | -322.49 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.